Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose MonitoringParts of the data have previously been presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, CA; June 9–13, 2017 and at the 17th Annual Diabetes Technology Meeting in Bethesda, MD, November 2–4, 2017.Trial number: DRKS00011920; registered at the Deutsches Register Klinischer Studien (German clinical trials register), an approved Primary Register in the WHO International Clinical Trials Registry Platform.
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: G5 [DG5] and FreeStyle Libre [FL]) are intended to replace blood glucose monitoring (BGM) and, according to manufacturer labeling, are distributed as such in some jurisdictions, including the United States and the European Union. METHODS: The measurement performance of these two systems in comparison with a BGM system was analyzed in a 14-day study with 20 participants comprising study site visits, which included phases of induced rapid glucose changes, and home use phases. Performance analysis was mainly based on deviations between CGM readings and BGM results. Sensor-to-sensor precision was also analyzed. RESULTS: Approximately 25% of DG5 and FL results showed differences from BGM results exceeding 15 mg/dL or 15% (at glucose concentration below or above 100 mg/dL, respectively) at times of therapeutic decisions, and ∼5% of differences exceeded 30 mg/dL or 30%. Performance was different depending on the setting (study site visits, home use phases, and phases of induced rapid glucose changes). In consensus error grid (CEG) analysis, both systems showed >99.5% of results within the clinically acceptable zones A and B. CONCLUSIONS: In this study, both systems showed deviations from blood glucose (BG) measurements, the current standard approach in diabetes therapy. Although a large percentage of results was found in CEG zones A and B, for approximately one in four therapeutic decisions, CGM and BG readings differed by at least 15 mg/dL or 15%. Such deviations should be taken into account when using CGM systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893 · cited 1×
“Considering that users of these systems reportedly perform only few additional BG measurements (2.8 measurements per day for DG5, 20 including two BG measurements for calibration, and 0.5 measurements per day for FL 21 ), nonadjunctive use seems to be already practiced by some CGM users.”
InfluentialThe Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685 · cited 1×
“26 While DG5 and FL measurement performance results were comparable to what had been published previously for each of the systems separately, 1,2,27 qualitative differences between DG5 and FL were found.”
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“…use of these CGM systems in people with type 1 diabetes mellitus or type 2 diabetes mellitus reported no change in time spent in the glucose target range, 20–23 suggesting that using CGM instead of BGM for therapeutic decisions might not affect the quality of diabetes therapy in the short term.”
Parkes, J. L., Slatin, S. L., Pardo, S., & Ginsberg, B. H. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1143 · Cited by 620
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329 · cited 6×
“For DG5, results based on the LOCF approach were slightly higher (i.e., worse) than using interpolated data.”
InfluentialClinical accuracy of a continuous glucose monitoring system with an advanced algorithm
Bailey, T. S., Chang, A., & Christiansen, M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814559746 · Cited by 168
Cited by
Lee, I., Probst, D., Klonoff, D., & Sode, K. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113054 · Cited by 288
Measures of Accuracy for Continuous Glucose Monitoring and Blood Glucose Monitoring Devices
Freckmann, G., Pleus, S., Grady, M., Setford, S., & Levy, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818812062 · Cited by 202
Self-citationFreckmann, G., Eichenlaub, M., Waldenmaier, D., Pleus, S., Wehrstedt, S., Haug, C., Witthauer, L., Jendle, J., Hinzmann, R., Thomas, A., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231190941 · Cited by 86
“117 We therefore recommend describing the method for pairing in sufficient detail, also because most studies (51.9”
InfluentialSelf-citationStandardization process of continuous glucose monitoring: Traceability and performance
Freckmann, G., Nichols, J. H., Hinzmann, R., Klonoff, D. C., Ju, Y., Diem, P., Makris, K., & Slingerland, R. J. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.025 · Cited by 62
Self-citationClinical approaches to treat impaired awareness of hypoglycaemia
Farrell, C. M., & McCrimmon, R. J. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211000248 · Cited by 31
Metadata
- Authors
- Freckmann, G., Link, M., Pleus, S., Westhoff, A., Kamecke, U., & Haug, C.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-08
- Volume
- 20
- Issue
- 8
- Pages
- 541-549
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2960340768
- Cited by
- 64
- References
- 7
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.